Deutsche Bank Ag\ Gilead Sciences, Inc. Call Options Transaction History

Deutsche Bank Ag\

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2020 May 14, 2020	SELL	$62.63 - $80.22 $17,912 - $22,942	-286 Reduced 31.57%	620 $46,000
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $41,452 - $46,484	670 Added 283.9%	906 $61,000
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $6,503 - $7,285	-104 Reduced 30.59%	236 $15,000
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $137,910 - $179,962	-2,278 Reduced 87.01%	340 $21,000
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $185,114 - $204,955	-2,597 Reduced 49.8%	2,618 $201,000
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $210,859 - $245,960	3,250 Added 165.39%	5,215 $369,000
Q1 2018 May 15, 2018	SELL	$72.84 - $88.8 $100,519 - $122,544	-1,380 Reduced 41.26%	1,965 $147,000
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $2,632 - $3,090	37 Added 1.12%	3,345 $239,000
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $238,539 - $282,734	3,308	3,308 $267,000

1,926

992M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.